Cefaclor (JP14/USP) en es it fr

Cefaclor (JP14/USP) Brand names, Cefaclor (JP14/USP) Analogs

Cefaclor (JP14/USP) Brand Names Mixture

  • No information avaliable

Cefaclor (JP14/USP) Chemical_Formula


Cefaclor (JP14/USP) RX_link


Cefaclor (JP14/USP) fda sheet

Cefaclor_(JP14/USP) FDA

Cefaclor (JP14/USP) msds (material safety sheet)

Cefaclor_(JP14/USP) MSDS

Cefaclor (JP14/USP) Synthesis Reference

R. R. Chauvette, U.S. Pat. 3,925,372 (1975)

Cefaclor (JP14/USP) Molecular Weight

367.808 g/mol

Cefaclor (JP14/USP) Melting Point

327 oC

Cefaclor (JP14/USP) H2O Solubility

8.6 mg/mL

Cefaclor (JP14/USP) State


Cefaclor (JP14/USP) LogP


Cefaclor (JP14/USP) Dosage Forms

Capsule; Powder; Powder for solution; Powder for suspension; Suspension

Cefaclor (JP14/USP) Indication

For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.

Cefaclor (JP14/USP) Pharmacology

Cefaclor is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A ß-hemolytic streptococci). Gram-negative aerobes - Escherichia coli, Haemophilus influenzae (including ß-lactamase-producing ampicillin-resistant strains), Klebsiella sp, and Proteus mirabilis.

Cefaclor (JP14/USP) Absorption

Well absorbed after oral administration, independent of food intake.

Cefaclor (JP14/USP) side effects and Toxicity

Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.

Cefaclor (JP14/USP) Patient Information

Patients should be counseled that antibacterial drugs including Ceclor should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Ceclor is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Ceclor or other antibacterial drugs in the future.

Cefaclor (JP14/USP) Organisms Affected

Enteric bacteria and other eubacteria